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Abstract
Cardiac biomarkers (CB) were first developed for assisting the diagnosis of cardiac events, especially acute
myocardial infarction. The discoveries of other CB, the better understanding of cardiac disease process and the
advancement in detection technology has pushed the applications of CB beyond the ‘diagnosis’ boundary. Not
only the measurements of CB are more sensitive, the applications have now covered staging of cardiac disease,
timing of cardiac events and prognostication. Further, CB have made their way to the intensive care setting where
their uses are not just confined to cardiac related areas. With the better understanding of the CB properties, CB
can now help detecting various acute processes such as pulmonary embolism, sepsis-related myocardial
depression, acute heart failure, renal failure and acute lung injury. This article discusses the properties and the uses
of common CB, with special reference to the intensive care setting. The potential utility of “multimarkers” approach
and microRNA as the future CB are also briefly discussed.
Introduction
Blood cardiac biomarkers (CB) have become increasingly
accurate for evaluating cardiac abnormalities during the
past 40 years. Initially, with the focus on myocardial
infarction (MI), the use of creatinine kinase-MB (CK-
MB), first described in 1972, was a major step forward
in the development of a highly cardiac-specific biomar-
ker. The introduction of cardiac troponin (cTn) assays
in 1989 was the next major advance, and subsequent
refinement of the assays now has the definition of acute
myocardial infarction (AMI) centered on it. This pro-
gression ironically has brought considerable difficulties
to the critical care physician who deals with multiorgan
failure rather than the patient presenting to the emer-
gency department with chest pain or single-organ
pathology. The recent penetration of high-sensitivity
(hs) cTn, replacing the fourth-generation cTn assays
further compounds these diagnostic challenges.
Moving beyond a sole focus on MI, the search for
alternative and supplementary serum markers to assist
in unravelling the presence, severity, and type of cardiac
injury has been intense (Figure 1). Whilst cardiac ische-
mia/infarction is the most prevalent cause of cardiac
injury with biomarker development reflecting this, the
search for more meaningful biomarkers now includes
CB for inflammatory processes and myocardial wall
stress (as a result of pressure or volume overload) where
evaluation extends beyond myocardial necrosis. The
important role of C-reactive protein (CRP) as a prognos-
tic marker is an example of the former while natriuretic
peptides are now accepted as clinically useful markers of
cardiac stress.
In the critical care setting, the challenge of confound-
ing factors brings about interpretation difficulties.
Clarity in diagnosis and/or guidance for management
frequently present when the heart is the only organ
affected, such as in the emergency department or cardi-
ology ward, does not always hold in the intensive care
unit (ICU) setting. Even so, an understanding of the
commonly used CB can be very helpful for cardiac eva-
luation of the critically ill patient.
Classes of cardiac biomarkers
The search for clinically useful CB has resulted in a
large number of circulating plasma substances being
investigated. These can be broadly grouped temporally
into three major categories: inflammatory, acute muscle
injury, and cardiac stress (Figure 2).
Biomarkers for inflammatory processes
Cardiac wound healing after MI can be divided into four
phases: phase 1 begins with the actual death of myocytes
commencing within 6 hours and continuing for up to 4
days; the phase 2 is that of an inflammatory response
beginning 12-16 hours after onset of ischemia; phase 3
is when granulation tissue begins forming at the infarct
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repair and begins at 2-3 weeks, persisting for up to a
year [1]. Although a number of immune mediators,
including cytokines, autoantibodies to myosin and tro-
pomyosin, as well as interferon (IFN)-g have been clo-
sely studied, clinically useful circulating inflammatory
biomarkers to assist in the diagnosis and prognosis of
AMI have yet to be established [2].
Where an infective agent is responsible for myocardial
damage, acute viral myocarditis being the prototype,
once again clinically helpful inflammatory biomarkers
are not available. Temporally, three phases exist when
myocardial damage is due to infection: 1) myocyte
destruction by the virus; 2) an innate immune response,
which ultimately may cause more harm than good; and
3) possible myocardial damage, resulting in a dilated
cardiomyopathy, and where once again, autoantibodies
may play a role [3,4].
What often is overlooked is the role of inflammation
in the progression of coronary artery disease (CAD),
Figure 1 The development of cardiac biomarkers. ADM, adrenomedullin; BNP, B-type natriuretic peptide; CAM, cell adhesion molecule; CK-
MB, creatine kinase-MB; CRP, C-reactive protein; cTn, cardiac troponin; H-FABP, human fatty-acid binding protein; HSP, heat shock protein; IL,
interleukin; IMA, ischemia-modified albumin; INFg, interferon g; LP-LPA2, lipoprotein-associated phospholipase A2; PAPP, pregnancy-associated
plasma protein; ROS, reactive oxygen species; sCD40L, soluble CD40 ligand.
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role of inflammatory markers hold more promise [5].
Unfortunately in the critical care setting, where organs
other than the heart are usually compromised, the speci-
ficity of these markers, including tumor necrosis factor
(TNF)-a, CD-40L, interleukins (IL-18, IL-6, IL-33, and
IL-1a), CRP, fibrinogen, pentraxin 3, and matrix metal-
loproteinases, are markedly compromised. The potential
of inflammatory markers is promising however, and
even in apparently nonimmune settings, such as emo-
tional stress-induced acute onset cardiomyopathy,
inflammatory pathways appear to play a pivotal part [6].
Biomarkers of myocardial injury
Cardiac troponins (cTn)
The evolving story of cTn to diagnose acute myocardial
damage is as fascinating as it is beguiling. The troponin
era began with the development of a double antibody,
two-step enzyme immunoassay for TnT in 1989 [7].
Evolution of these developments now has cTn as the
central component of the definition of an AMI [8]. The
superior diagnostic power of cTn is demonstrated by
correlation with histological findings [9]. A diagnosis of
AMI is predicted on the detection of an increase or
decrease of cTn, with at least one value > 99% percentile
upper reference limit (URL) in patients with evidence of
myocardial ischemia. This evolution extended the role
of Tn from being a marker only for AMI to that of
acute coronary syndrome (ACS) and secondary myocar-
dial damage from conditions, such as pulmonary embo-
lus (PE), cardiac trauma, and chemotherapy-induced
myocardial damage. The latest step in the evolution is
the development and rapid uptake of the hs-cTn assays
around the world.
Comparison of cTnT and cTnI
The cTn complex, consisting of three proteins (C, I, and
T) encoded by different genes, plays a pivotal role in the
modulation of calcium-dependant sarcomere contraction
[10,11]. cTnI and cTnT have cardio-specific isoforms
not found in skeletal muscle, making for highly specific
markers of myocardial damage. Both cTnI and cTnT are
released from necrotic myocardium, ischemic and nonis-
chemic-induced, as intact proteins and degradation pro-
ducts [12]. Although experimental data indicates that
cTn only leaks out of the cell after cell death, the find-
ing of cTn in marathon runners and after inducible
myocardial ischemia, raises the possibility of it occurring
in the absence of necrosis [13,14]. The cTnT assay is
only available from one manufacturer, whereas cTnI
assays are available from a number of vendors, render-
ing interpretation confusing because of the lack of stan-
dardization. It is important that the clinician has an
understanding of the assay used in their institution,
including analytical quality and limitations. Increasing
sophistication of the assays has resulted in fewer false-
negatives and false-positives; however, the presence of
cTn autoantibodies in the blood or marked hemolysis
can produce inaccurate results [15,16].
cTn as a diagnostic marker
The central consideration in the interpretation of an ele-
vated serum cTn is that it is a marker of myocardial
damage, but on its own it does not determine the etiol-
ogy of the damage. cTnT and cTnI demonstrate similar
diagnostic ability in detection of myocardial damage
despite analytical differences [17]. The criteria for diag-
nosing an AMI are a rising or falling pattern of blood
cTn levels in association with clinical features of myo-
cardial ischemia. An international taskforce comprising
of the American Heart Association/World Health Foun-
dation/European Society of Cardiology/American Col-
lege of Cardiology Foundation (AHA/WHF/ESC/ACCF)
recommends a cutoff value set at 99
th percentile of
URL, or the concentration at which the assay achieves a
coefficient of variation of 10% if that exceeds the 99
th
percentile [8,18]. Clinical features of AMI include classi-
cal symptoms, ECG changes, regional wall motion
Figure 2 Evolution of cardiac dysfunction and the associated changes in cardiac biomarkers. (see legend to Figure 1 for abbreviations).
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myocardium. In the absence of these features, an alter-
native cause of the cTn elevation and myocardial
damage should be sought (Table 1).
The timing of cTn elevations becomes increasingly
important with the development of more sensitive assays
and an understanding of the manner in which cTn is
released from the damaged myocyte is helpful. An acute
process involves a rise and fall with an increase occur-
ring 2-4 hours after symptoms and remaining elevated
for 7-14 days. Therefore, serial measurements, usually 3-
6 hours apart are recommended [19]. The less sensitive
cTn assays require significant elevations, whereas the
newer hs-cTn assay requires smaller ones. Biological
variation may become more important at these lower
levels bringing other challenges to interpreting the result
[20]. If the initial cTn level is not elevated, then serial
measurements over 6-9 hours are necessary. If this sec-
ond sample is still not elevated but clinical suspicion of
an MI remains high, then a further sample at 12-24
hours should be considered. An earlier resampling at 3
hours still provides approximately 80% sensitivity in
detecting AMI [21]. Age seems to be a confounding fac-
tor. A study that included 1,098 patients who underwent
a single hs-cTn sample on presentation to the emer-
gency department with symptoms suggestive of an AMI
identified the best cutoff value, separating AMIs from
non-AMIs, to be much higher. The hs-cTnT value for
patients older than aged 70 years at 54 ng/l was nearly
four times the 99
th percentile, although close to the 99
th
percentile for two different hs-cTnI assays [22].
The introduction of hs-cTn, with precision sensitivity
improved from the μg/l to the ng/l range, has
enhanced the sensitivity and reduced the time to diag-
nose AMI in the acute setting. The use of a single hs-
cTnI measurement at 3 hours in patients presenting
with chest pain, using a cutoff of 40 ng/l, gave a nega-
tive predictive value (NPV) of 84.1% and positive pre-
dictive value (PPV) of 86.7%; these findings predicted a
30% increase in cTn levels at 6 hours [23]. The diag-
nostic accuracy of a number of different hs-cTn assays
were found to be excellent and much superior to the
standard assays [24]. Interpretation is reliant upon the
baseline level, the increase at a selected time interval
(usually 6 hours), and the clinical setting. For example,
whereas hs-cTnT assay has a cutoff value of 14 ng/l, a
second sample at 6 hours is recommended when the
value is between 14-100 ng/l to improve the specificity
and PPV of the assay. A single reading above 100 ng/l
is considered a high risk for ACS and warrants man-
agement accordingly. When testing for the optimal
change of cTnI, Apple found a ≥ 30% increase from
baseline (admission) level in the 4-10 hours follow-up
measurements provided a sensitivity of 71% and speci-
ficity of 91% [25]. Giannitsis and associates demon-
strated that, compared with the 4
th generation cTnT,
the admission hs-cTnT assay (at a cutoff of 99
th per-
centile) detected more evolving non-STEMI cases
(61.5% vs. 7.7%). The detection by hs-cTnT further
improved to 100% within 6 hours. The overall diagno-
sis of MI increased by 34.6% [26]. A doubling of the
hs-cTnT concentration within 3 hours in the presence
of a second concentration ≥ 99
th percentile is asso-
ciated with a PPV of 100% and NPV of 88% [26]. Such
an approach, or a variant of it, is suitable for the devel-
opment of protocols in the emergency department but
unfortunately less so in the ICU where confounding
issues are present.
The sedated hemodynamically unstable patient on
positive pressure ventilation does not usually provide
the classical symptoms of myocardial ischemia. ECG
changes, often on a background of an already abnormal
ECG, are nonspecific, and confounding factors, such as
renal failure or heart failure, are present. Many condi-
tions commonly found in an ICU are associated with
elevated cTn levels, even in the absence of definite cor-
onary artery pathology leading to myocardial ischemia
(Table 1). Added to this is the likelihood that many MI
will be a type II class as described in the international
consensus guidelines (Table 2).
Table 1 Conditions commonly associated with cTn
elevations
Arrhythmias*
Aortic dissection*
Acute heart failure*
Coronary vasospasm*
Cardiomyopathy, e.g., postpartum
Coronary vasculitis, e.g., SLE, Kawasaki Syndrome*
Cardiac contusion
Chemotherapy
Hypertension*
Myocarditis
Pulmonary embolus
Sepsis/septic shock
SIRS
Takotsubo cardiomyopathy
Renal failure
Severe neurological disorders
Pulmonary hypertension - severe
Radiofrequency ablation*
Pericarditis
Extreme exertion
*Elevations of cTn in the absence of overt ischemic heart disease or in the
patient with normal coronary arteries include those patients with myocardial
ischemia from noncoronary disease, and by definition come into the MI type
II classification. Certain conditions result in chronic elevations of cTn, including
chronic renal failure, chronic heart failure, stable CAD, marked left ventricular
wall hypertrophy, and aortic stenosis [11].
McLean and Huang Annals of Intensive Care 2012, 2:8
http://www.annalsofintensivecare.com/content/2/1/8
Page 4 of 11The advent of hs-cTn brings a definite improvement
in diagnostic accuracy but at the expense of lower speci-
ficity, a challenge already encountered on a daily basis in
the ICU with standard assays. However, this develop-
ment should be seen as a positive step with the higher
diagnostic accuracy, but further studies in the critically
ill population are required to better define its use in this
population.
Cardiac troponin as a prognostic marker
Elevated cTn is associated with poor prognosis in
patients with acute ischemia [27,28]. cTnI and cTnT
have comparable prognostic performance, except for
patients with chronic renal failure where cTnT but not
cTnI was a predictor of a worse outcome [29]. It is
noteworthy that the prognostic value of cTn is not lim-
ited to ischemic heart disease. In a systematic review of
an elevated cTn in critically ill patients, looking at 23
studies involving 4,492 patients, Lim and colleagues
found a 2.5 times increased risk of death and an
increased length of ICU stay of 3 days and hospital stay
of 2.2 days [30].
Creatine kinase-MB
When first described in 1972, the electrophoresis meth-
ods required for separation of the cardiac isoenzymes
had low analytical specificity [31]. An immunoinhibition
method resulted in a useful clinical test and creatine
kinase-MB (CK-MB), in combination with aspartate
transaminase and lactate dehydrogenase, became the
triad of biomarkers used for the diagnosis of AMI. CK-
MB, is released within 2-4 hours, peaks at 24 hours fol-
lowing pressure overload or ischemia, and returns to
normal by 36-72 hours [32]. It is a sensitive marker of
MI, but a single measurement on presentation has low
sensitivity. Lack of specificity is a problem; 10% of
patients experience chest pain with an elevated CK-MB
but normal cTn [33]. It is present in small amounts in
skeletal muscle (1-3% of total CK), and a large muscle
injury can be compounded by the re-expression of pro-
teins producing the CK-MB isoenzyme [34]. The advent
of cTn has relegated CK-MB, previously the favorite
cardiac biomarker of myocardial necrosis, into the back-
ground and its role in the critically ill patient has been
superseded.
Fatty acid binding proteins (FABPs)
Fatty acid binding proteins (FABPs)–small proteins
located in the cytoplasm–facilitate transport of fatty
acids and other lipids within the cell. Heart-type FABP
(H-FABP) is a sensitive marker of myocyte damage and,
unlike troponin, is released by both ischemia and necro-
sis. It also is released more rapidly than troponin,
although the advent of hs-cTn will overcome the advan-
tage of FABP in this regard. H-FABP is released from
the damaged cell within 1-3 hours, returning to normal
by 12-24 hours. It is now available as a point of care
test for the diagnosis of AMI in many countries and
also has good data to support its use in prognostication
from MI [35,36]. The diagnostic sensitivity of H-FABP
for cardiac injury is 93.1%, higher than CK-MB and cTn
[37]. There is a dearth of information about the use of
H-FABP for the diagnosis of MI in the critically ill
population; however, there may be a role in the risk
stratification of pulmonary embolism (PE) in critically ill
patients.
Biomarkers of cardiac stress
Natriuretic peptides (NP)
Primarily for maintaining osmotic and cardiovascular
homeostasis, the NP family includes multiple peptides
and receptors. Present throughout all vertebrate classes,
including fish, amphibians, mammals, and birds, this
family of related peptides and specific receptors is an
integral system in the control of hydromineral balance
and blood pressure [38]. In mammals, the NPs include
atrial natriuretic peptide (ANP), brain or B-type
natriuretic peptide (BNP), C-type natriuretic peptide
(CNP), dendroaspis natriuretic peptide (DNP), and uro-
dilatin. They share similar structures, with ANP, BNP,
and CNP having a ring of 17 amino acids, 11 of which
are identical. Urodilatin and ANP having an identical
Table 2 Different types of myocardial infarction
Types of myocardial
infarction
Clinical classification
Type 1 Spontaneous myocardial infarction related to ischemia due to primary coronary event.
Type 2 Myocardial infarction secondary to ischemia due to increased oxygen demand or decreased supply, e.g., coronary artery
spasm, coronary embolism, anemia, arrhythmias, hypertension, or hypotension.
Type 3 Sudden, unexpected cardiac death with symptoms and signs of cardiac ischemia. Death occurs before blood cardiac
biomarkers able to be measured.
Type 4a Myocardial infarction associated with percutaneous
Intervention.
Type 4b Myocardial infarction associated with stent thrombosis as documented by angiography or at autopsy.
Type 5 Myocardial infarction associated with coronary artery bypass surgery.
Abridge version based on Reference [8]
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closely associated, with ANP and BNP inhibiting ET-1
release and ET-1 stimulating NP synthesis [39].
Although the earliest investigations into the applica-
tion of NP in everyday medicine involved ANP, with
more recent investigations on CNP, DNP, and urodila-
tin, BNP and NT-proBNP is where most effort has
been directed. The pre-prohormone BNP is a 134 ami-
noacid peptide synthesized in ventricular myocytes,
with subsequent cleaving into the 108 aminoacid pro-
hormone BNP, which is released into the circulation
during hemodynamic stress [40]. Corin, a circulating
endoprotease, cleaves the prohormone BNP into the
biologically active BNP (32 amino acids) and inactive
NT-proBNP (76 amino acids). BNP, having a half-life
of 20 minutes, is cleared by cells containing BNP
receptors, whereas NT-proBNP, which is cleared by
the kidney, has a longer half-life (60-120 minutes); this
explains the higher circulating concentrations com-
pared with BNP.
The obvious clinical applications of BNP and NT BNP
have led to the development of fully automated assays
for both; some understanding by the clinician of the
specific assay used is important, because some immu-
noassays cannot differentiate between active and inactive
forms. For example, some assays actually measure a
mixture of both BNP and NT-proBNP, whereas various
breakdown products of BNP may be included in the
assay [41].
Clinical application of BNP/NT-proBNP The clearest
clinical benefit of the application of BNP and NT-
proBNP has been the diagnosis and prognosis of heart
failure. Regular application in the emergency department
is based on studies such as Breathing Not Properly,
where a serum BNP level > 100 pg/ml was demon-
strated to diagnose congestive heart failure (CHF) with a
sensitivity of 90% and specificity 73% [42,43]. Similar
diagnostic accuracy was identified with NT-proBNP,
with a level of 500 ng/ml used by most investigators
[44,45]. BNP levels can be elevated in patients with
CAD, leading to search for a diagnostic and prognostic
role in this group [46,47].
Only a weak correlation between pulmonary capillary
w e d g ep r e s s u r ea n ds e r u mB N Pl e v e li nt h eI C Up a t i e n t
h a sb e e nf o u n d[ 4 8 ] .I nar e v i e wo nt h er o l eo fB N Pa n d
NT-proBNP in the management of heart failure, Omland
cautions the interpretation of elevated levels in the ICU
setting [49]. Our group, along with others, demonstrated
that there may be a role in discriminating those patients
with from those without cardiac dysfunction in the ICU
[50-52]. However, the actual type of cardiac dysfunction
is not clarified by the finding of an elevated BNP. Age
and gender also must be taken into account in the inter-
pretation of elevated serum levels [53].
The challenge is in translating the value of BNP in the
diagnosis of HF in the emergency department, or prog-
nostic value of CHF in the outpatient setting, to a role
in the critically ill patient. Usually multiple comorbid-
ities, particularly renal failure or sepsis, can cause eleva-
tion of serum levels in the absence of heart failure.
Numerous factors may contribute to the measurement
BNP level in the serum in a single patient (Figure 3).
Figure 3 Contributors to circulating BNP level.
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Numerous studies have sought to clarify a role for NPs as
prognostic markers in the ICU setting, yet the results
have been conflicting and insufficiently robust to modify
ap a t i e n t ’s management [54-58]. Although an elevated
NP most likely represents cardiac dysfunction even in the
critically ill patient, they lack discriminating power to
identify what type of cardiac dysfunction is present and
cannot be compared with the application of echocardio-
graphy, which should be routinely used in critically ill
patients with underlying cardiac dysfunction. A in-depth
review by Christenson concluded the utilization of BNP
or NT-BNP did not have a substantive role in the man-
agement of critically ill patients in the ICU [59].
Adrenomedullin (ADM)
A peptide of 52 amino acids, ADM is synthesized and
found in heart, adrenal medulla, lungs, and kidneys. In
the heart, it is produced in response to volume and
pressure overload and has similar actions to the NPs
[60]. It is a potent vasodilator, inducing diuresis and
natriuresis. Plasma ADM levels are significantly elevated
in heart failure and AMI, correlated with severity of ill-
ness, and have some prognostication for mortality in
AMI [61]. It is insufficiently characterized, especially in
regard to measurements and clear guidance as to what
elevation is important in the ICU setting.
Usefulness of cardiac biomarkers in noncoronary artery
pathologies commonly presenting the in ICU
Acute pulmonary embolus
CB can have roles in both the diagnosis and prognosis
of a patient with PE. Elevation of cTn results from
increased metabolic demand and reduced myocardial
perfusion, which causes right ventricular ischemia/
microinfarction, whereas increased wall stress results in
elevation of BNP. Kucher and Goldhaber in 2003 con-
cluded that a cTn below the cutoff required for that
required to diagnose AMI, or a BNP < 50 ng/ml, have a
> 98% negative predictive value for in hospital death by
PE [62]. La Vecchia and associates demonstrated that a
cTnI > 0.06 μg/L was associated with a subsequent mor-
tality of 36% compared with those < 0.06 μg/L, and the
former had a greater need for inotropes and mechanical
ventilation [63]. The role of NP is less certain, and
although some investigators regard NT-proBNP as a
better prognosticator than currently used clinical scores
in PE, any additional value over cTn or H-FABP in
acute PE is not proven [64].
The role of CB in risk stratification is firmly estab-
lished, and CB are included as principal markers in the
European Society of Cardiology guidelines on the diag-
nosis and management of acute pulmonary embolus
[65]. The presence of elevated cTn and/or BNP places
the patient outside the low risk category ( < 1%
mortality), and when combined with echo features of
cardiac dysfunction and hypotension place the patient in
the high-risk ( > 15% mortality) category. The combina-
tion of specific CB and echocardiographic abnormalities
has important management ramifications in regards to
consideration of thrombolytic therapy for acute PE, even
in the hemodynamically stable patient [62,66].
H-FABP seems to have better diagnostic accuracy
and better prognostic value compared with cTn and
BNP in cases of PE. Puls and associates in a study of
107 patients found that normal H-FABP on admission
predicts an absence of significant complications or
death. The PPV for H-FABP was 41% compared with
29% for cTn and 19% for proBNP [67]. In a more
recent study involving 101 consecutive patients with
confirmed PE and echocardiographic signs of right
ventricular overload, but without hypotension or
shock, none of the patients with normal H-FABP (N =
87) on admission to the emergency department experi-
enced clinical deterioration, required inotropic support,
or died. In the H-FABP-positive group (n = 14), the
degree of RV dysfunction was greater, ten had clinical
deterioration that required inotropic support, and eight
died [68].
Sepsis
It has been recognized for more than a decade that ele-
vated cTn in septic patients is associated with a higher
mortality [69]. cTn is elevated in 12-85% of ICU patients
with sepsis of severe inflammatory syndrome, with a
meta-analysis including 3,278 patients from 20 studies,
giving a median value of 43% [30].
The wide range of prevalence probably relates to the
heterogeneity found in septic studies but clearly an ele-
vated cTn is not uncommon. The real uncertainty
comes from the cause of the troponin release, whether
it is global myocardial ischemia (i.e., type II AMI), the
myocytoxic effects of cytokines, reactive oxygen species
or endotoxins, or exacerbation of chronic coronary
artery small vessel disease [70]. cTnI also was elevated
in septic patients who display evidence of isolated and
reversible diastolic dysfunction [71]. Adding to the
uncertainty is whether any such myocyte damage is per-
sistent, with autopsy studies not necessarily revealing
irreversible damage in shocked patients with premortem
elevated cTns [72].
In a study of 207 patients with severe sepsis and septic
shock, circulating cTnT was detected in 60% of the
patients using the fourth-generation cTnT assays and
100% by the hs-cTnT assay [73]. The levels of hs-cTnT
were associated with disease severity and survival,
although it was not an independent predictor of in-hos-
pital mortality. The authors proposed a potential role
for hs-cTn in sepsis as an early marker of shock.
Although NP levels are elevated in sepsis, there is
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outcome information [54,74].
Acute heart failure: non-CAD
cTn is elevated in patients with HF even in the
absence of CAD [75,76]. Lacking diagnostic sensitivity
and specificity for the diagnosis of heart failure, it is
associated with increased risks of mortality and cardiac
morbidity [77-79]. For example, elevated cTnI predicts
mortality in patients hospitalized for congestive heart
failure [75].
Renal failure
Because baseline serum cTn levels are already elevated
in chronic renal failure (CRF), the diagnosis of a MI is
based on > 20% increase in levels at 6-9 hours after pre-
sentation [80]. This recommendation by the National
Academy of Clinical Biochemistry Laboratory is based
on the “older” cTn assays, and the situation has become
more challenging with a recent study that demonstrated
that in a cohort of asymptomatic patients with end-
stage renal disease, 100% had a hs-cTn level > 99% per-
centile value [81]. In a comparison of the prognostic
value of cTn and BNP/NT-proBNP in 143 CRF patients
on dialysis, Hickman and associates demonstrated that
NT-proBNP was superior to cTn [82].
Acute lung injury and weaning
Although classically a “cardiac biomarker,” BNP has per-
haps best found a role in the ICU in the diagnosis of
hypoxic respiratory failure and determining the optimal
timing for extubation. Rana and colleagues found that a
BNP level < 250 pg/ml supports the diagnosis of acute
lung injury (AUC = 0.71), with improved accuracy when
patients with renal failure were excluded (AUC = 0.82)
[83]. Other studies use varying cutoff serum BNP levels
and have different diagnostic accuracy reducing the clin-
ical usefulness of a single sample [84].
A recent study of 100 patients, who underwent a 48-
hour spontaneous breathing trial before extubation,
underwent echocardiographic evaluation and NP sam-
pling immediately before the trial commenced and at
t h ee n d ,b e f o r ee x t u b a t i o n .Ab a s e l i n ec u t o f fB N Pl e v e l
of 263 ng/l and 1,343 ng/l for NT-proBNP before the
trial, or an increase of 48 and 21 ng/l respectively for
BNP and NT-proBNP, accurately predicted those
patients who failed extubation as a result of underlying
cardiac failure. BNP performed better than NT-proBNP
[85]. A prior study recruited patients who received
mechanical ventilation for > 24 hours demonstrated that
baseline BNP was higher in patients with subsequent
weaning failure and correlated to weaning duration [86].
Multimarker diagnosis of cardiac dysfunction
The use of multiple biomarkers has the theoretical
attraction of improving both sensitivity and specificity in
the diagnosis of different cardiac disorders, with
particular relevance in the ICU where multiple con-
founding factors exist. The combination of cTnT, ECG,
and ischaemia-modified albumin identified ischemia in
95% of patients presenting with chest pain [87]. How-
ever, other studies do not support the benefit of multi-
markers compared with a single one in the emergency
department or ICU [88,89].
In predicting 6-month mortality from acute heart fail-
ure, Nunez and associates demonstrated the combina-
tion of CA-125 and BNP added prognostic value to that
provided by BNP alone [90].
Potentially future cardiac biomarkers
M i c r o R N A s( a l s ok n o w na sm i R so rm i R N A s )a r e
approximately 20-25 nucleotide long noncoding ribonu-
cleic acids (RNAs) that negatively regulate or inhibit
gene expression by binding to sites in the 3’ untrans-
lated region of targeted messenger RNAs [91-94]. They
have been found to be involved in almost every biologi-
cal process, from cellular differentiation and prolifera-
tion to cell death and apoptosis. Many different types of
miRNAs can be detected in circulating blood, and these
m i R N A sa r ep r e s e n ti nar e m a r k a b l ys t a b l ef o r mt h a t
even withstand repetitive freezing/thawing cycles and
are protected against RNases. Of the thousands of miR-
NAs described to date in humans, many exhibit tissue-
specific patterns of expression can be detected in circu-
lating blood. Ones that regulate the cardiovascular sys-
tem have been identified [95-97]. They can be divided
into four groups:
1. miRNAs regulating endothelial function and angio-
genesis: miR126, miR17-92 cluster (miR17, miR20a,
miR92a), miR130a, miR221, miR21
2. Cardiac myocyte-specific mRNA: miR208a
3. Cardiac myocyte (highly expressed) and skeletal
muscle miRNAs: miR1, miR 133a, miR499.
Smooth muscle miRNAs: miR143, miR145
Since the half-life of circulating miRNA is counted in
hours and their breakdown do not seem to be compro-
mised by the presence of organ dysfunction, they hold
promise as very specific, accurate markers of cardiac
dysfunction in the critically ill patient.
Conclusions
Measuring plasma CB is often a routine undertaking for
most critical care physicians, and the increasingly accu-
rate markers developed over the years have an impor-
tant place in everyday practice. The obvious advantages
experienced in the emergency department or cardiology
ward are not always shared in the ICU where cofoun-
ders frequently make for a more cautious interpretation
and careful consideration of subsequent management
decisions. Yet, an understanding of the underlying
strengths and weaknesses now available from a
McLean and Huang Annals of Intensive Care 2012, 2:8
http://www.annalsofintensivecare.com/content/2/1/8
Page 8 of 11considerable research and clinical database should lead
to an appreciation of their immense value.
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